Two experimental therapies from Vicore Pharma and Endeavor BioMedicines that could provide new ways of treating idiopathic pulmonary fibrosis (IPF) have shown encouraging
Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic
A digital therapeutic developed by Vicore Pharma and Alex Therapeutics has been shown to reduce the psychological burden of living with pulmonary fibrosis (PF) in a pivota
Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficu
A new project has been launched to develop artificial intelligence models that more closely reflect the diversity seen in patients with lung disease in the UK.
Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised